PHARMACY

CaryRx brings prescription delivery to D.C. through Postmates

BY David Salazar

WASHINGTON — CaryRx and PostMates are bringing same-day delivery to patients in the Washington, D.C. metro area through their partnership. CaryRx’s mobile app lets patients upload paper prescriptions with a photo or transfer existing prescriptions. Prescriptions can be delivered within one hour within the area or scheduled for future delivery, the company said. 

“We are excited to bring this invaluable service to Washington D.C.," CaryRx founder and CEO Areo Nazari said. "Our goal is to provide an amazing patient experience not readily available throughout the country while constantly innovating to bridge the gap between pharmacies, patients and prescribers. Backed by a truly technology infused pharmacy, our proprietary platform is vertically integrated for seamless and efficient fulfillment of prescription deliveries."

The CaryRx app features a secure live chat with its pharmacy team, refill reminders, visual prescription management and express delivery through Postmates as the delivery service’s first prescription fulfillment partner.

“Our theme from day one has been automation of our pharmacy backend,” Nazari said. “The backend integration with Postmates expands on that theme and gives us the fastest prescription delivery experience available in the country with a delivery logistics platform that can scale with our volume.”

CaryRx, which is available in the Apple App Store, accepts most insurance plans and is expanding its network. VP business development Kevin Lance said that delivery would be free, and that patients can expect the same co-pay as at their brick-and-mortar pharmacy.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AmerisourceBergen’s pharmaceutical distribution segment drives Q3 revenue increase

BY David Salazar

VALLEY FORGE, Pa. — AmerisourceBergen on Thursday reported its third quarter results, posting a 4.9% increase in revenue, which hit $38.7 billion. The company’s gross profit declined 2.5% to $1.1 billion, which it attributed to a $121 million decrease in gains from antitrust litigation settlements and a decrease in the pharmaceutical distribution services segment.

“AmerisourceBergen continues to execute successfully in a dynamic marketplace. We are providing our customers with the highest quality pharmaceutical distribution services and the most innovative solutions to grow their businesses,” AmerisourceBergen chairman, CEO and president Steve Collis said. “For example, we are fully rolling out and implementing our innovative ABC Order platform — an ordering system designed by pharmacists for pharmacists that completely changes the way independent pharmacies manage their product orders. Early customer feedback on the platform has been extremely positive, with pharmacists citing ease of use and real-world business value.”

The company’s pharmaceutical distribution services segment saw revenue of $37 billion, a 4.7% increase over the same quarter last year, with the AmerisourceBergen Drug Corp. seeing a revenue increase of 4.5% due largely to organic sales growth. AmerisourceBergen Specialty Group posted a 10.3% revenue increase, marking the 14th consecutive quarter that the specialty arm has seen revenue growth over 10%. As a result of the company’s decision to  combing ABDC and ABSG into a single operating segment, the company eliminated the $1.5 billion in intrasegment revenue from its total segment revenue presentation.

The segment’s operating income of $377 million represented an 8.7% drop compared to the same quarter last year. The company attributed the dip in operating income to the decline in segment gross profit, which was impacted by lower price appreciated and a prior-year customer contract renewal.

In the company’s other segment — which encompasses its consulting services business, World Couriers and MWI Animal Health, it reported $1.7 billion in revenue, which was 106% higher than it was in the third quarter of 2016.  The segment’s operating income increased 14.8% to $95 million.

Thursday’s results were accompanied by a change in the company’s 2017 guidance, which is now projecting revenue growth of about 5%, compared with its previous assumption of 5.5% to 6.5%.

The company recently concluded its Good Neighbor Pharmacy’s ThoughtSpot conference and trade show, where it unveiled its DIR fee estimator tool and a revamped ABC Order platform. It also recently opened a new distribution center in Seattle.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA clears hepatitis C drug Mavyret

BY David Salazar

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug to treat adults with chronic hepatitis C virus genotypes 1-6. Mavyret, from AbbVie, was approved for HCV patients without cirrhosis or with mild cirrhosis, including patients with moderate to severe kidney disease and those on dialysis.

The FDA said that Mavyret is the first treatment of eight-week duration for all hepatitis C genotypes.

“This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients with genotype 1 infection, the most common HCV genotype in the United States, who were not successfully treated with other direct-acting antiviral treatments in the past,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.

AbbVie EVP research and development and chief scientific officer Dr. Michael Severino said, “The approval of Mavyret demonstrates AbbVie's commitment to advancing science to help address unmet needs by delivering a new cure for patients who historically had limited treatment options.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?